Cellular therapy

Ronit Reich-Slotky; Yen Michael S. Hsu; Joseph Schwartz

doi:10.1016/B978-0-12-803999-1.00017-1

Cellular therapy

Ronit Reich-Slotky
, Yen Michael S. Hsu
, Joseph Schwartz

School of Medicine

New York Presbyterian Hospital

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Cellular therapy is quickly becoming an integral part of transfusion medicine practice. Therefore, transfusion medicine professionals are required to be familiar with the practice of manufacturing therapeutic cellular products for clinical use. This chapter is designed with practical questions allowing for comprehension of the fundamental knowledge and important clinical issues in cellular therapy. The topics covered by this chapter include evaluating the manufacturing of various hematopoietic progenitor cells (HPCs) products, reviewing the donor eligibility/suitability for HPCs collections, and also understanding the unique challenges of HPC mobilization/collection. The chapter also provides relevant clinical scenarios, such as specific transfusion support for patients receiving HPC transplantation with ABO-incompatible stem cell graft. Last, the chapter highlights the relevant FDA regulations that are critical in the field of cellular therapy.

Original language	English
Title of host publication	Transfusion Medicine, Apheresis, and Hemostasis
Subtitle of host publication	Review Questions and Case Studies
Publisher	Elsevier
Pages	401-421
Number of pages	21
ISBN (Electronic)	9780128039991
ISBN (Print)	9780128040300
DOIs	https://doi.org/10.1016/B978-0-12-803999-1.00017-1
State	Published - 20 Sep 2017

Keywords

Apheresis
Donor eligibility
Hematopoietic progenitor cells
Mobilization
Stem cell transplant
Transfusion

Access to Document

10.1016/B978-0-12-803999-1.00017-1

Cite this

@inbook{a007b2ec8d6a4b98bf6fbddca9ab0c77,

title = "Cellular therapy",

abstract = "Cellular therapy is quickly becoming an integral part of transfusion medicine practice. Therefore, transfusion medicine professionals are required to be familiar with the practice of manufacturing therapeutic cellular products for clinical use. This chapter is designed with practical questions allowing for comprehension of the fundamental knowledge and important clinical issues in cellular therapy. The topics covered by this chapter include evaluating the manufacturing of various hematopoietic progenitor cells (HPCs) products, reviewing the donor eligibility/suitability for HPCs collections, and also understanding the unique challenges of HPC mobilization/collection. The chapter also provides relevant clinical scenarios, such as specific transfusion support for patients receiving HPC transplantation with ABO-incompatible stem cell graft. Last, the chapter highlights the relevant FDA regulations that are critical in the field of cellular therapy.",

keywords = "Apheresis, Donor eligibility, Hematopoietic progenitor cells, Mobilization, Stem cell transplant, Transfusion",

author = "Ronit Reich-Slotky and Hsu, \{Yen Michael S.\} and Joseph Schwartz",

year = "2017",

month = sep,

day = "20",

doi = "10.1016/B978-0-12-803999-1.00017-1",

language = "English",

isbn = "9780128040300",

pages = "401--421",

booktitle = "Transfusion Medicine, Apheresis, and Hemostasis",

publisher = "Elsevier",

}

TY - CHAP

T1 - Cellular therapy

AU - Reich-Slotky, Ronit

AU - Hsu, Yen Michael S.

AU - Schwartz, Joseph

PY - 2017/9/20

Y1 - 2017/9/20

N2 - Cellular therapy is quickly becoming an integral part of transfusion medicine practice. Therefore, transfusion medicine professionals are required to be familiar with the practice of manufacturing therapeutic cellular products for clinical use. This chapter is designed with practical questions allowing for comprehension of the fundamental knowledge and important clinical issues in cellular therapy. The topics covered by this chapter include evaluating the manufacturing of various hematopoietic progenitor cells (HPCs) products, reviewing the donor eligibility/suitability for HPCs collections, and also understanding the unique challenges of HPC mobilization/collection. The chapter also provides relevant clinical scenarios, such as specific transfusion support for patients receiving HPC transplantation with ABO-incompatible stem cell graft. Last, the chapter highlights the relevant FDA regulations that are critical in the field of cellular therapy.

AB - Cellular therapy is quickly becoming an integral part of transfusion medicine practice. Therefore, transfusion medicine professionals are required to be familiar with the practice of manufacturing therapeutic cellular products for clinical use. This chapter is designed with practical questions allowing for comprehension of the fundamental knowledge and important clinical issues in cellular therapy. The topics covered by this chapter include evaluating the manufacturing of various hematopoietic progenitor cells (HPCs) products, reviewing the donor eligibility/suitability for HPCs collections, and also understanding the unique challenges of HPC mobilization/collection. The chapter also provides relevant clinical scenarios, such as specific transfusion support for patients receiving HPC transplantation with ABO-incompatible stem cell graft. Last, the chapter highlights the relevant FDA regulations that are critical in the field of cellular therapy.

KW - Apheresis

KW - Donor eligibility

KW - Hematopoietic progenitor cells

KW - Mobilization

KW - Stem cell transplant

KW - Transfusion

UR - https://www.scopus.com/pages/publications/85054350939

U2 - 10.1016/B978-0-12-803999-1.00017-1

DO - 10.1016/B978-0-12-803999-1.00017-1

M3 - Chapter

AN - SCOPUS:85054350939

SN - 9780128040300

SP - 401

EP - 421

BT - Transfusion Medicine, Apheresis, and Hemostasis

PB - Elsevier

ER -

Cellular therapy

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this